Do the Cyclooxygenase-2 inhibitors accentuate the cognitive activities?

Cognition is a process of knowing. When it is impaired, reviving is needed. Studies to bustle off the psychomotor activities using non steroidal anti-inflammatory drugs revealed variable results. The aim of this study is to evaluate the effects of single oral dose of celecoxib and meloxicam on cognitive activity in healthy, young volunteers. Fourteen healthy young volunteers were participated, allocated into two groups. After a7-day washed-out period, each volunteer was randomly given a single oral dose of either celecoxib or meloxicam or placebo. Psychomotor tests were performed to record participants' sensory and motor reactions. placebo-administered subjects had non-significant changes in both choice reaction time and critical flicker fusion. Celecoxib-administered participants had a significantly reduced recognition reaction time without a significant effect on motor reaction time. While meloxicam-administered participants had a significant reduction in motor reaction time without a significant effect on recognition reaction time. All drug-given participants had a non-significant change in choice reaction time when compared with corresponding baseline and placebo values. Cox-2 inhibitors have no place in improving the cognition

Acetylator phenotype in Iraqi patients with allergic contact dermatitis

Few studies have been done on acetylator status in ACD. This study determined acetylator status in Iraqi patients with allergic contact dermatitis [ACD] in comparison to a matched control group. The study included 35 ACD patients and 67 healthy volunteers. The ACD patients were diagnosed clinically and the diagnosis was confirmed by patch test. A detailed history was taken from the patients. After an overnight fast, each control subject and each patient received a single oral dose of 100 mg of dapsone. A blood sample was collected after 3 hours and plasma was separated for determination of dapsone and monoacetyldapsone by HPLC. Twenty-six of the 35 ACD patients returned for follow up. The frequency of slow acetylators in healthy individuals was 71.6%, while the frequency of rapid acetylators was 28.4%. The frequency of slow acetylators in ACD patients was 60.0% while the frequency of rapid acetylators was 40.0%. There was no association between the acetylator status, personal history of allergy, patch-test positivity or sites of dermatitis in ACD patients. A rapid acetylator status might predispose to ACD, but does not seem to influence other features of the disease